Search Results - "Sanborn, Rachel"

Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study by Antonia, Scott, Prof, Goldberg, Sarah B, MD, Balmanoukian, Ani, MD, Chaft, Jamie E, MD, Sanborn, Rachel E, MD, Gupta, Ashok, MD, Narwal, Rajesh, PhD, Steele, Keith, PhD, Gu, Yu, PhD, Karakunnel, Joyson J, MD, Rizvi, Naiyer A, Prof

“…Summary Background PD-L1 and CTLA-4 immune checkpoints inhibit antitumour T-cell activity. Combination treatment with the anti-PD-L1 antibody durvalumab and…”
Get full text

Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial by Nishio, Makoto, Barlesi, Fabrice, West, Howard, Ball, Simon, Bordoni, Rodolfo, Cobo, Manuel, Longeras, Pascale Dubray, Goldschmidt, Jr, Jerome, Novello, Silvia, Orlandi, Francisco, Sanborn, Rachel E, Szalai, Zsuzsanna, Ursol, Grigoriy, Mendus, Diana, Wang, Lijia, Wen, Xiaohui, McCleland, Mark, Hoang, Tien, Phan, See, Socinski, Mark A

“…We report the final results of the phase 3 IMpower132 study evaluating atezolizumab plus carboplatin or cisplatin plus pemetrexed (APP) in patients with…”
Get more information

Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study by Park, Keunchil, Haura, Eric B, Leighl, Natasha B, Mitchell, Paul, Shu, Catherine A, Girard, Nicolas, Viteri, Santiago, Han, Ji-Youn, Kim, Sang-We, Lee, Chee Khoon, Sabari, Joshua K, Spira, Alexander I, Yang, Tsung-Ying, Kim, Dong-Wan, Lee, Ki Hyeong, Sanborn, Rachel E, Trigo, José, Goto, Koichi, Lee, Jong-Seok, Yang, James Chih-Hsin, Govindan, Ramaswamy, Bauml, Joshua M, Garrido, Pilar, Krebs, Matthew G, Reckamp, Karen L, Xie, John, Curtin, Joshua C, Haddish-Berhane, Nahor, Roshak, Amy, Millington, Dawn, Lorenzini, Patricia, Thayu, Meena, Knoblauch, Roland E, Cho, Byoung Chul

“…Non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor ( ) exon 20 insertion (Exon20ins) mutations exhibits inherent resistance to approved…”
Get full text

Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial by Ascierto, Paolo Antonio, Lipson, Evan J, Dummer, Reinhard, Larkin, James, Long, Georgina V, Sanborn, Rachel E, Chiarion-Sileni, Vanna, Dréno, Brigitte, Dalle, Stéphane, Schadendorf, Dirk, Callahan, Margaret K, Nyakas, Marta, Atkinson, Victoria, Gomez-Roca, Carlos Alberto, Yamazaki, Naoya, Tawbi, Hussein A, Sarkis, Naomey, Warad, Deepti, Dolfi, Sonia, Mitra, Priyam, Suryawanshi, Satyendra, Grob, Jean-Jacques

“…Nivolumab and relatlimab activity in advanced melanoma with prior progression on anti-programmed death-1/programmed death ligand 1 (PD-(L)1)-containing…”
Get full text

Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer by Massard, Christophe, Gordon, Michael S, Sharma, Sunil, Rafii, Saeed, Wainberg, Zev A, Luke, Jason, Curiel, Tyler J, Colon-Otero, Gerardo, Hamid, Omid, Sanborn, Rachel E, O'Donnell, Peter H, Drakaki, Alexandra, Tan, Winston, Kurland, John F, Rebelatto, Marlon C, Jin, Xiaoping, Blake-Haskins, John A, Gupta, Ashok, Segal, Neil H

“…To investigate the safety and efficacy of durvalumab, a human monoclonal antibody that binds programmed cell death ligand-1 (PD-L1), and the role of PD-L1…”
Get full text

Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study by Horn, Leora, Infante, Jeffrey R, Reckamp, Karen L, Blumenschein, George R, Leal, Ticiana A, Waqar, Saiama N, Gitlitz, Barbara J, Sanborn, Rachel E, Whisenant, Jennifer G, Du, Liping, Neal, Joel W, Gockerman, Jon P, Dukart, Gary, Harrow, Kimberly, Liang, Chris, Gibbons, James J, Holzhausen, Allison, Lovly, Christine M, Wakelee, Heather A

“…Evaluate safety and determine the recommended phase II dose (RP2D) of ensartinib (X-396), a potent anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor…”
Get full text

Phase I, First-in-Human Study of the Probody Therapeutic CX-2029 in Adults with Advanced Solid Tumor Malignancies by Johnson, Melissa, El-Khoueiry, Anthony, Hafez, Navid, Lakhani, Nehal, Mamdani, Hirva, Rodon, Jordi, Sanborn, Rachel E, Garcia-Corbacho, Javier, Boni, Valentina, Stroh, Mark, Hannah, Alison L, Wang, Song, Castro, Henry, Spira, Alexander

“…PROCLAIM-CX-2029 is a phase I first-in-human study of CX-2029, a Probody-drug conjugate targeting CD71 (transferrin receptor 1) in adults with advanced solid…”
Get full text

Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions by Zhou, Caicun, Tang, Ke-Jing, Cho, Byoung Chul, Liu, Baogang, Paz-Ares, Luis, Cheng, Susanna, Kitazono, Satoru, Thiagarajan, Muthukkumaran, Goldman, Jonathan W, Sabari, Joshua K, Sanborn, Rachel E, Mansfield, Aaron S, Hung, Jen-Yu, Boyer, Michael, Popat, Sanjay, Mourão Dias, Josiane, Felip, Enriqueta, Majem, Margarita, Gumus, Mahmut, Kim, Sang-We, Ono, Akira, Xie, John, Bhattacharya, Archan, Agrawal, Trishala, Shreeve, S Martin, Knoblauch, Roland E, Park, Keunchil, Girard, Nicolas

“…Amivantamab has been approved for the treatment of patients with advanced non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor ( ) exon 20…”
Get full text

Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205 by Dhodapkar, Madhav V, Sznol, Mario, Zhao, Biwei, Wang, Ding, Carvajal, Richard D, Keohan, Mary L, Chuang, Ellen, Sanborn, Rachel E, Lutzky, Jose, Powderly, John, Kluger, Harriet, Tejwani, Sheela, Green, Jennifer, Ramakrishna, Venky, Crocker, Andrea, Vitale, Laura, Yellin, Michael, Davis, Thomas, Keler, Tibor

“…Immune-based therapies for cancer are generating substantial interest because of the success of immune checkpoint inhibitors. This study aimed to enhance…”
Get more information

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial by Rizvi, Naiyer A, Dr, Mazières, Julien, Prof, Planchard, David, MD, Stinchcombe, Thomas E, MD, Dy, Grace K, MD, Antonia, Scott J, MD, Horn, Leora, MD, Lena, Hervé, MD, Minenza, Elisa, MD, Mennecier, Bertrand, MD, Otterson, Gregory A, MD, Campos, Luis T, MD, Gandara, David R, MD, Levy, Benjamin P, MD, Nair, Suresh G, MD, Zalcman, Gérard, Prof, Wolf, Jürgen, Prof, Souquet, Pierre-Jean, MD, Baldini, Editta, MD, Cappuzzo, Federico, MD, Chouaid, Christos, MD, Dowlati, Afshin, MD, Sanborn, Rachel, MD, Lopez-Chavez, Ariel, MD, Grohe, Christian, Prof, Huber, Rudolf M, Prof, Harbison, Christopher T, PhD, Baudelet, Christine, PhD, Lestini, Brian J, MD, Ramalingam, Suresh S, Prof

“…Summary Background Patients with squamous non-small-cell lung cancer that is refractory to multiple treatments have poor outcomes. We assessed the activity of…”
Get full text

Monitoring Therapeutic Response and Resistance: Analysis of Circulating Tumor DNA in Patients With ALK+ Lung Cancer by Horn, Leora, Whisenant, Jennifer G, Wakelee, Heather, Reckamp, Karen L, Qiao, Huan, Leal, Ticiana A, Du, Liping, Hernandez, Jennifer, Huang, Vincent, Blumenschein, George R, Waqar, Saiama N, Patel, Sandip P, Nieva, Jorge, Oxnard, Geoffrey R, Sanborn, Rachel E, Shaffer, Tristan, Garg, Kavita, Holzhausen, Allison, Harrow, Kimberly, Liang, Chris, Lim, Lee P, Li, Mark, Lovly, Christine M

“…Despite initial effectiveness of ALK receptor tyrosine kinase inhibitors (TKIs) in patients with ALK+ NSCLC, therapeutic resistance will ultimately develop…”
Get more information

OX40 is a potent immune-stimulating target in late-stage cancer patients by Curti, Brendan D, Kovacsovics-Bankowski, Magdalena, Morris, Nicholas, Walker, Edwin, Chisholm, Lana, Floyd, Kevin, Walker, Joshua, Gonzalez, Iliana, Meeuwsen, Tanisha, Fox, Bernard A, Moudgil, Tarsem, Miller, William, Haley, Daniel, Coffey, Todd, Fisher, Brenda, Delanty-Miller, Laurie, Rymarchyk, Nicole, Kelly, Tracy, Crocenzi, Todd, Bernstein, Eric, Sanborn, Rachel, Urba, Walter J, Weinberg, Andrew D

“…OX40 is a potent costimulatory receptor that can potentiate T-cell receptor signaling on the surface of T lymphocytes, leading to their activation by a…”
Get full text

Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial by Cho, Byoung Chul, Kim, Dong-Wan, Spira, Alexander I., Gomez, Jorge E., Haura, Eric B., Kim, Sang-We, Sanborn, Rachel E., Cho, Eun Kyung, Lee, Ki Hyeong, Minchom, Anna, Lee, Jong-Seok, Han, Ji-Youn, Nagasaka, Misako, Sabari, Joshua K., Ou, Sai-Hong Ignatius, Lorenzini, Patricia, Bauml, Joshua M., Curtin, Joshua C., Roshak, Amy, Gao, Grace, Xie, John, Thayu, Meena, Knoblauch, Roland E., Park, Keunchil

“…Patients with epidermal growth factor receptor ( EGFR )-mutated non-small cell lung cancer (NSCLC) often develop resistance to current standard…”
Get full text

Results of Lung Cancer Screening in the Community by Handy, Jr, John R, Skokan, Michael, Rauch, Erika, Zinck, Steven, Sanborn, Rachel E, Kotova, Svetlana, Wang, Mansen

“…To address doubts regarding National Lung Screening Trial (NLST) generalizability, we analyzed over 6,000 lung cancer screenings (LCSs) within a community…”
Get full text

Cancer's Dark Matter: Lighting the Abyss Unveils Universe of New Therapies by Fox, Bernard A, Urba, Walter J, Jensen, Shawn M, Page, David B, Curti, Brendan D, Sanborn, Rachel E, Leidner, Rom S

“…The authors of a recent study identified noncanonical peptides (NCP) presented by cancer cells' HLA and observed lack of reactivity to these antigens by…”
Get full text

Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial by Boni, Valentina, Fidler, Mary J, Arkenau, Hendrik-Tobias, Spira, Alexander, Meric-Bernstam, Funda, Uboha, Nataliya, Sanborn, Rachel E, Sweis, Randy F, LoRusso, Patricia, Nagasaka, Misako, Garcia-Corbacho, Javier, Jalal, Shadia, Harding, James J, Kim, Stella K, Miedema, Iris H C, Vugts, Danielle J, Huisman, Marc C, Zwezerijnen, Gerben J C, van Dongen, Guus A M S, Menke van der Houven van Oordt, C Willemien, Wang, Song, Dang, Tam, Zein, Ivan A, Vasiljeva, Olga, Lyman, Susan K, Paton, Virginia, Hannah, Alison, Liu, Joyce F

“…Praluzatamab ravtansine (CX-2009) is a conditionally activated Probody drug conjugate (PDC) comprising an anti-CD166 mAb conjugated to DM4, with a…”
Get full text

First‐In‐Human, First‐In‐Class, Phase I Trial of the Fucosylation Inhibitor SGN‐2FF in Patients with Advanced Solid Tumors by Do, Khanh T., Chow, Laura Quan Man, Reckamp, Karen, Sanborn, Rachel E., Burris, Howard, Robert, Francisco, Camidge, D. Ross, Steuer, Conor E., Strickler, John H., Weise, Amy, Specht, Jennifer M., Gutierrez, Martin, Haughney, Peter, Hengel, Shawna, Derleth, Christina Louise, Yap, Timothy A.

“…Lessons Learned Inhibition of glycoprotein fucosylation, as monotherapy and in combination with immune checkpoint blockade, is a promising therapeutic strategy…”
Get full text

Real-world burden of chemotherapy-induced myelosuppression in patients with small cell lung cancer: a retrospective analysis of electronic medical data from community cancer care providers by Epstein, Robert S, Weerasinghe, Roshanthi K, Parrish, Amy S, Krenitsky, JoAnn, Sanborn, Rachel E, Salimi, Tehseen

“…Chemotherapy-induced myelosuppression, which commonly exhibits as neutropenia, anemia, or thrombocytopenia, represents a substantial burden for patients with…”
Get more information

Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial by Bullock, Andrea J., Schlechter, Benjamin L., Fakih, Marwan G., Tsimberidou, Apostolia M., Grossman, Joseph E., Gordon, Michael S., Wilky, Breelyn A., Pimentel, Agustin, Mahadevan, Daruka, Balmanoukian, Ani S., Sanborn, Rachel E., Schwartz, Gary K., Abou-Alfa, Ghassan K., Segal, Neil H., Bockorny, Bruno, Moser, Justin C., Sharma, Sunil, Patel, Jaymin M., Wu, Wei, Chand, Dhan, Rosenthal, Katherine, Mednick, Gabriel, Delepine, Chloe, Curiel, Tyler J., Stebbing, Justin, Lenz, Heinz-Josef, O’Day, Steven J., El-Khoueiry, Anthony B.

“…Microsatellite stable metastatic colorectal cancer (MSS mCRC; mismatch repair proficient) has previously responded poorly to immune checkpoint blockade…”
Get full text

Non-small cell lung cancer with MET amplification: review of epidemiology, associated disease characteristics, testing procedures, burden, and treatments by Yang, Mo, Mandal, Erin, Liu, Frank X, O'Hara, Jr, Richard M, Lesher, Beth, Sanborn, Rachel E

“…Mesenchymal-epidermal transition factor gene amplification ( amp) is being investigated as a therapeutic target in advanced non-small cell lung cancer (NSCLC)…”
Get full text